The biotech firm reports $7.6 million in cash and $4.0 million in short-term investments as of June 30, 2026.
Indaptus Therapeutics reported a second-quarter GAAP loss of $0.02 per share, matching its financial performance metrics. The company’s cash position improved, with $7.6 million in cash and cash equivalents and $4.0 million in short-term investments as of June 30, 2026.
Management stated that liquidity has strengthened compared to the end of the first quarter, citing current operating plans and available resources. The firm did not provide further guidance on future earnings or operational updates.
No immediate market reaction was disclosed in the release.